Rapid small molecule testing 2bind offers end-to-end small molecule drug discovery support from protein purification to lead optimization, positioned to accelerate preclinical programs and reduce decision-cycle time for biopharma clients seeking faster go/no-go decisions.

GCI screening capabilities Recent launch of Grating-Coupled Interferometry based screening platform enables label-free kinetic screening and integrated workflows, presenting a differentiation point for clients needing high-throughput, quantitative binding data for small molecules.

Target feasibility emphasis Introduction of a standardized Target Feasibility Platform signals an opportunity to engage clients at the target validation stage, offering early biophysical evaluation to de-risk target selection and accelerate project prioritization.

Biologics and nucleics expansion Partnerships and service expansion into antibodies, biologics, and nucleic acid therapeutics through CNATM collaboration broaden the addressable market, allowing cross-sell into clients exploring diverse modality programs.

Engagement and credibility signals Active funding history and strategic collaborations, along with a modernized website and ongoing platform launches, reinforce credibility with potential clients and can be leveraged to approach biotech firms seeking trusted CROs for early-stage discovery and de-risked development.